05 Sep 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Global pharmaceutical giants Mylan and Teva are planning to launch manufacturing units in the city of Indore, India, with likely investments of $147.05 million and $88.23 million respectively.
This was highlighted by the general secretary of Indian Drug Manufacturers Association (IDMA), Mr Dara Patel, at a recent conference. However, on contacting, Mylan and Teva officials declined to reveal any details about the projects.
Indore is an emerging metropolitan city of India and is home to several large and medium scale pharmaceutical companies like Ranbaxy, IPCA, Plethico, Piramal, PDPL, Syncom, Lupin, and Advance Enzyme, among others.